Amicus Therapeutics Files 2025 Proxy Statement

Ticker: FOLD · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1178879

Amicus Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form TypeDEF 14A
Filed DateApr 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

Related Tickers: AMTX

TL;DR

Amicus Therapeutics (AMTX) filed its proxy statement for the June 5th meeting. Vote your shares!

AI Summary

Amicus Therapeutics, Inc. filed its definitive proxy statement on April 24, 2025, for its annual meeting of stockholders scheduled for June 5, 2025. The filing, designated as DEF 14A, outlines the company's governance and proposals to be voted on by shareholders. Key items likely include the election of directors and executive compensation.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, executive pay, and important corporate decisions, enabling them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is standard for public companies and does not inherently introduce new risks.

Key Players & Entities

  • AMICUS THERAPEUTICS, INC. (company) — Registrant
  • 0001140361-25-015479 (filing_id) — Accession Number
  • 20250424 (date) — Filing Date
  • 20250605 (date) — Meeting Date
  • 47 HULFISH STREET (address) — Principal Business Address
  • PRINCETON (location) — City
  • NJ (location) — State
  • 08542 (zip_code) — Zip Code

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with the proxy statement for Amicus Therapeutics, Inc.'s annual meeting of stockholders, detailing information for voting on corporate matters.

When is the annual meeting of stockholders scheduled?

The annual meeting of stockholders is scheduled for June 5, 2025.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on April 24, 2025.

What is the company's principal business address?

The company's principal business address is 47 Hulfish Street, Princeton, NJ 08542.

What is the SEC file number for Amicus Therapeutics, Inc.?

The SEC file number for Amicus Therapeutics, Inc. is 001-33497.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding AMICUS THERAPEUTICS, INC. (FOLD).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.